Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

The Miami Lakes, Florida-based company presented 12-month results from the SUCCESS PTA study at the Charing Cross Symposium ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Clinical findings show association between nadunolimab and lower incidence and later onset of CIPN Preclinical data show ...

Cordis announced new data from the SUCCESS PTA and SELUTION SFA Japan peripheral studies evaluating the company’s Selution ...

Patients will receive relacorilant in combination with nab-paclitaxel and bevacizumab. “In our pivotal Phase 3 ROSELLA trial, treatment with relacorilant and nab-paclitaxel improved patients ...

Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment ...

Novocure (NVCR) announced that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields therapy for ...

Corcept Therapeutics (CORT) announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating ...

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J. Clin. Oncol. 26, 5544–5552 (2008).